PRPO - Precipio, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4202
-0.0328 (-7.24%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.4530
Open0.4600
Bid0.4200 x 900
Ask0.4440 x 1300
Day's Range0.4200 - 0.4600
52 Week Range0.3600 - 20.0000
Volume670,093
Avg. Volume1,674,641
Market Cap8.265M
Beta2.06
PE Ratio (TTM)N/A
EPS (TTM)-7.1600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Precipio Launches ICE COLD-PCR™ Liquid Biopsy Kit for Pancreatic Cancer

    Specialty diagnostics company Precipio, Inc. (PRPO), today announced the launch of two additional ICEme™ kits using its proprietary ICE-COLD PCR™ liquid biopsy technology. The new RUO kits enable the detection of mutations in KRAS Exons 2 & 3, which include important predictive and prognostic biomarkers, and are available on both qPCR and Sanger molecular diagnostic platforms. The 5-year survival rate for stage I pancreatic cancer is ~14%, a number that drops to 3% for stage III patients, and 1% for stage IV patients1.

  • ACCESSWIRE7 days ago

    Today’s Research Reports on Stocks to Watch: Precipio and Teva Pharmaceutical

    NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Shares of Precipio and Teva were gaining full speed on Monday. Precipio shares exploded after the company announced a substantial preliminary unaudited first ...

  • GlobeNewswire8 days ago

    Precipio Announces Preliminary Q1 2018 Year-over-Year Revenue Increase of 286%

    Specialty diagnostics company Precipio, Inc. (PRPO), announces preliminary, unaudited 1st quarter 2018 revenues of approximately $712,000, representing a 286% increase from the same quarter in the prior year. “With the completion of our sales reorganization and increasing business stabilization, we are focused on aggressively capturing market share with our disruptive diagnostic products and services,” commented Ilan Danieli, CEO.

  • GlobeNewswire26 days ago

    Precipio Announces Participation Details for Upcoming Shareholder Conference Call

    Specialty diagnostics company Precipio, Inc. (PRPO), provides details of its previously announced upcoming shareholder conference call scheduled for Monday April 30, 2018 at 4:30PM EST, where management will provide an extensive strategic business update and will respond to questions submitted in advance via email. International callers should call 1-412-317-6789. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard’s Dana-Farber Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.

  • GlobeNewswire29 days ago

    Precipio Completes a $3M Convertible Debt Facility

    Specialty diagnostics company Precipio, Inc. (PRPO), announced today that it entered into a convertible debt financing facility of up to $3M, to be drawn down at the option of the company (See the company’s Form 8-K filed on April 23rd, 2018). New and existing investors participated in the financing, to be used for working capital, including for the potential growth initiatives described below. Despite a tight top talent market, Precipio has recently hired an experienced VP of Sales along with seasoned sales representatives that have already begun to increase revenues.

  • GlobeNewswirelast month

    Precipio in Strategic Partnership Discussions for Proprietary Cytogenetics Media IV-Cell

    NEW HAVEN, Conn., April 18, 2018-- Specialty diagnostics company Precipio, Inc., announced today it is in active licensing discussions with several potential partners regarding IV-Cell, Precipio’ s proprietary ...

  • GlobeNewswirelast month

    Precipio Releases its 2017 10-K, Files a form S-1, and hosts Fourth Quarter and Full Year Update Call

    Management to provide strategic business update to shareholders. NEW HAVEN, Conn., April 17, 2018-- Specialty diagnostics company Precipio, Inc., announced today that on April 13 th, 2018 it filed its ...

  • GlobeNewswirelast month

    Precipio Launches ICE COLD-PCR™ Research Access Program for Cancer Centers

    NEW HAVEN, Conn., April 11, 2018-- Specialty diagnostics company Precipio, Inc., announced today the launch of its program to provide complimentary ICE COLD-PCR kits to cancer researchers studying the ...

  • Precipio Inc (NASDAQ:PRPO): Time For A Financial Health Check
    Simply Wall St.last month

    Precipio Inc (NASDAQ:PRPO): Time For A Financial Health Check

    While small-cap stocks, such as Precipio Inc (NASDAQ:PRPO) with its market cap of US$5.18M, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...

  • GlobeNewswire2 months ago

    Important JAMA Article Underscores Superiority of Precipio’s Liquid Biopsy Core Technology

    NEW HAVEN, Conn., April 03, 2018-- Specialty diagnostics company Precipio, Inc., announced today that, in response to recent articles, its approach using ICE COLD-PCR™ liquid biopsy tests on Real-Time ...

  • GlobeNewswire2 months ago

    Precipio Files Patent for Non-Invasive Cell Capture Device For Gynecological Cancer Detection

    In collaboration with Yale, feminine panty liner designed to remove obstacles to early detection. NEW HAVEN, Conn., March 28, 2018-- Specialty diagnostics company Precipio, Inc., announced today the filing ...

  • GlobeNewswire2 months ago

    Precipio Enters India Liquid Biopsy Market with Adoption by Leading Laboratory

    NEW HAVEN, Conn., March 26, 2018-- Specialty diagnostic company Precipio, Inc., today announced a laboratory services agreement with CORE Diagnostics to offer ICE COLD-PCR™ liquid biopsy testing services ...

  • GlobeNewswire2 months ago

    Precipio Restructures Capitalization Table

    NEW HAVEN, Conn., March 22, 2018-- Specialty diagnostics company Precipio, Inc., in an 8- K issued today announced an agreement with investors in certain 2017 underwritten and registered direct offerings, ...

  • GlobeNewswire2 months ago

    Precipio Integrates Cost Reducing and Fast Turnaround "High Resolution Melt" into Liquid Biopsy Platform

    NEW HAVEN, Conn., March 20, 2018-- Specialty diagnostics company Precipio, Inc., announced today it has successfully incorporated the use of High Resolution Melt technology into its ICE COLD-PCR™ kits, ...

  • GlobeNewswire2 months ago

    Precipio Settles Lawsuit with Crede Capital

    NEW HAVEN, Conn., March 13, 2018-- Specialty diagnostics company Precipio, Inc., announced today it has settled its lawsuit with Crede Capital Group LLC, restructuring the final substantial liability of ...

  • GlobeNewswire3 months ago

    Key Measure of Precipio’s Pathology Sales Growth 4X Prior Quarter

    NEW HAVEN, Conn., Feb. 22, 2018-- Precipio, Inc., announced today that within the first half of Q1-2018 it has set up trials for pathology lab services with 4 times as many new oncology customers as in ...